TIDMNSCI
RNS Number : 0007V
NetScientific PLC
13 April 2016
NetScientific plc
("NetScientific" or the "Company" or the "Group")
NetScientific Portfolio Company PDS Biotechnology will embark on
multiple Phase 2 studies following positive results following the
completion of its Phase I study for PDS0101 Immunotherapy for
HPV-Related Cancers
London, UK - 13/4/2016 - NetScientific plc (AIM: NSCI), the
transatlantic healthcare technology group, is pleased to announce
that its therapeutics portfolio company, PDS Biotechnology, will
today announce positive Phase I study results for its PDS0101
immunotherapy for HPV-Related Cancers. In addition, NetScientific
intends to make a further investment of $500,000 into PDS
Biotechnology. To date, NetScientific has invested GBP1.76m in PDS
Biotechnology and has a shareholding of 14.85%.
The Phase 1 study was performed in cervical neoplasia subjects
infected with high-risk cancer-causing strains of HPV. Key study
goals included the evaluation of human safety and tolerability, and
confirmation of the method of action employed by Versamune(R),
PDS's proprietary technology platform, by causing induction of high
levels of active HPV-specific killer T-cells. The Phase 1 study
demonstrated that PDS0101 successfully overcomes a key
immunotherapy obstacle by efficiently accessing the immunological
pathway known as MHC Class-I, necessary in humans to train and
activate a population of T-cells known as 'killer' T-cells to
target cancers containing specific "cancer proteins".
Commenting on the news, NetScientific's Chief Executive Officer,
Francois R. Martelet said: "We are encouraged by these promising
Phase I results, which provide validation of the Versamune(R)
platform technology. As an early stage investor in PDS
Biotechnology we look forward to continuing our support of the
Company as it looks to further corroborate the potential of PDS0101
in upcoming phase 2 studies in pre-cancer, cervical and head and
neck cancers."
The full text of the announcement from PDS Biotechnology can be
found below.
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Mark Nanovich, Interim
CFO
Investec (NOMAD and Tel: +44 (0)20 7597 4000
broker)
Gary Clarence / Daniel
Adams
Consilium Strategic
Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / netscientific@consilium-comms.com
Chris Gardner / Jessica
Hodgson / Chris Welsh
/ Laura Thornton
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net.
PDS Biotechnology Reports Positive Phase 1 Study Results for
PDS0101 Immunotherapy for HPV-Related Cancers
- Achieved substantial induction of killer T-cells capable of targeting HPV-positive tumors
- Well tolerated; no significant toxicities
- On track to initiate multiple Phase 2 studies in HPV-related cancers in next 12 months
North Brunswick, NJ: PDS Biotechnology has completed a
successful Phase 1 clinical study of its lead cancer immunotherapy,
PDS0101, focused on the treatment of HPV-induced cancers. These
include head and neck, anal, and cervical cancer, as well as anal,
vaginal, penile, vulvar and cervical pre-cancerous neoplasias.
PDS0101 is based on the company's proprietary Versamune(R)
platform, which is being applied to multiple immuno-oncology
products.
The PDS0101 Phase 1 study was performed in cervical neoplasia
subjects infected with high-risk cancer-causing strains of HPV. Key
study goals included evaluation of human safety and tolerability,
and confirmation of the Versamune(R) platform's mechanism of action
that causes induction of high levels of active HPV-specific killer
T-cells. The Phase 1 study demonstrated that PDS0101 successfully
overcomes a key immunotherapy obstacle by efficiently accessing the
immunological pathway known as MHC Class-I, necessary in humans to
train and activate a population of T-cells known as killer T-cells
to target cancers containing specific "cancer proteins."
Dr. Frank Bedu-Addo, CEO said, "PDS regards these strong human
immunological responses, paired with a superior safety profile, as
extremely promising, especially given that T-cell induction was
seen in all subjects."
In preclinical studies, PDS0101 demonstrated a unique ability to
down-regulate key populations of immune-suppressive cells, leading
to strong anti-tumor efficacy. Successful development of
immunotherapies, especially of cancer vaccines, has historically
been impeded by an inability to effectively activate tumor-specific
killer T-cells and also overcome immune-suppression.
The ability of PDS0101 to conclusively demonstrate human
efficacy by inducing high levels of tumor-specific killer T-cells,
while simultaneously reducing immune-tolerance, will be further
corroborated in upcoming phase 2 studies in pre-cancer, cervical
and head and neck cancers.
About the Versamune(R) Platform: Versamune(R) is a synthetic
nanotechnology that exploits the immune system's natural
inclination to efficiently take up the nanoparticles upon
subcutaneous injection. Versamune(R) then facilitates efficient
presentation of cancer protein antigens to the killer T-cells, thus
training the T-cells to recognize the cancer. It has also been
proven to activate critical immunological signaling pathways that
result in the production of immunological proteins known as
cytokines and chemokines locally within the lymph nodes to recruit
T-cells, and enhance T-cell proliferation as well as the killing
activity of T-cells. Activation of these pathways may also be
responsible for the technology's ability to overcome tumor immune
suppression.
About PDS Biotechnology: PDS Biotech is a clinical stage
immuno-oncology company committed to the development of simpler,
safer and more effective immunotherapies. An example of the
company's approach is the Versamune(R) platform, possibly the first
immuno-oncology technology to successfully combine the three
critical attributes of an effective immunotherapy in a simple
nanoparticle, while also eliminating the potentially debilitating
toxicities of some leading immunotherapy approaches. PDS
Biotechnology's oncology pipeline includes products for prostate,
ovarian, breast and colorectal cancers, in addition to its lead
PDS0101 program for several HPV-related cancers.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESFMGMDZZVGVZZ
(END) Dow Jones Newswires
April 13, 2016 02:00 ET (06:00 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
